Yi Lin

Yi Lin is a leading expert in cellular therapies and bispecific antibodies for multiple myeloma. Her clinical research has advanced both CAR-T cell therapy and bispecific antibody treatments for myeloma, contributing to multiple FDA approvals. Lin has led pivotal trials of BCMA-targeting therapies and continues to develop combination strategies.

林义是多发性骨髓瘤细胞治疗和双特异性抗体的领先专家。她的临床研究推进了骨髓瘤的CAR-T细胞治疗和双特异性抗体治疗，为多个FDA批准做出了贡献。林义领导了BCMA靶向治疗的关键试验，并继续开发组合策略。